Francesca Sedda

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

F. Meloni, M. Carta, M. Campagna, 2021, Clinical and Experimental Medicine.

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

F. Meloni, M. Carta, M. Campagna, 2021, Clinical and Experimental Medicine.

Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis

S. Rapposelli, A. Perra, A. Columbano, 2023, Frontiers in Oncology.

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

F. Meloni, M. Carta, M. Campagna, 2021, Vaccines.

A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G

M. Carta, A. Perra, S. Giglio, 2023, Frontiers in Immunology.